Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients
Part of paid clinical trials in Miami, Florida.
- Sponsor
- Genfit
- Study ID
- NCT03765671
- Phase
- PHASE1
- Status
- Completed
Conditions
- Hepatic Impairment
- Liver Disease
- Pharmacokinetics
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Accepted
Interventions
- Elafibranor — DRUG120mg oral single dose
Study Details
This study is being conducted in order to assess the need for dose adjustment for elafibranor in patients with hepatic impairment. Pharmacokinetic parameters of elafibranor and its active metabolite (GFT1007) will be compared in hepatic impaired patients (mild, moderate and severe according to Child-Pugh categories) versus healthy participants after a single oral administration of elafibranor 120 mg.
Key Dates
- Start date
- Dec 12, 2018
- Status verified
- Aug 2019
- Primary completion
- Jun 7, 2019
- Completion
- Jun 14, 2019
Study Design
- Enrollment
- 30 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- BASIC_SCIENCE
Arms
- Experimental: Mild Child-Pugh ASingle oral dose of elafibranor 120mg
- Experimental: Moderate Child-Pugh BSingle oral dose of elafibranor 120mg
- Experimental: Severe Child-Pugh CSingle oral dose of elafibranor 120mg
- Experimental: HealthySingle oral dose of elafibranor 120mg
Primary Outcome Measure
Area under curve from dosing time to last measurement (AUC(0-t)) of elafibranor and active metabolite [ Time Frame: pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for hepatic impaired patients ]
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Division of Clinical Pharmacology, University of Miami | Miami | Florida | 33136 | - |
| inVentiv Health Clinical Research | Miami | Florida | 33136 | - |
Find similar trials in Miami, FL
Related Studies
- Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434PHASE1 · Recruiting · Vir Biotechnology, Inc. · Rialto, California
- Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)PHASE1 · Recruiting · Ensysce Biosciences · Miami, Florida
- Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic ImpairmentPHASE1 · Recruiting · Daiichi Sankyo · Miami, Florida
- Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic FunctionPHASE1 · Recruiting · Atea Pharmaceuticals, Inc. · Orlando, Florida